Right, they don't have completed mice study results, as that's a material event. But I am sure they are looking at everything that Sunshine is working on, and right now the COVID treatment and adva-27a cancer treatment have the highest value of RoI potential, but I think the cancer generics have potentially the quickest turnaround for the company to put out a product to bring in profit.
I don't remember where, but I believe it said the timetable to get SBFM's COVID pill on the market was a year, if everything pans out. I believe with the generics it's a matter of some distribution fees and then production time, but they could potentially bring in money sooner than the potential COVID pill. Not to mention the generics are proven as viable cancer treatments. If I were a company I would want some reassurance that some money can be made on a $23 million investment, and right now the two potential big money compounds are by no means a sure thing.